TX-MAVENIR
29.5.2024 15:01:32 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that its world-leading SpamShield messaging fraud prevention technology is driving a steep decline in the volume of spam and scam messages for Globe Telecom, Inc. in the Philippines – demonstrating its ability to disincentivize scammers and successfully boost customer protection against fraudulent, malicious and nuisance messaging. The Philippines is one of the large SMS markets in the world, and addressing the aggressive growth in the volume of spam and scam messaging is a key priority for the government’s National Telecommunications Commission (NTC).
In an impressive year-on-year improvement, Mavenir’s SpamShield has enabled the Philippines’ largest mobile operator to achieve a record 67% drop in blocked spam and scam SMS, plus a 74% decline in bank-related spam and scam messages during the first quarter of 2024, compared with the same period in 2023. The total number of blocked spam and scam SMS messages fell substantially from 1.1 billion in Q1 2023 to 362.8 million in Q1 2024. Over the same time span, the number of scam SMS messages directly reported by customers declined 44% year-on-year – from 610 in Q1 2023 to 342 in Q1 2024. Mavenir’s SpamShield technology has delivered an immediate and measurable impact for Globe – which reported blocking over 5 billion spam and scam messages in 2023 – by significantly raising the technical barriers to send fraudulent campaigns, increasing the cost of fraud, and removing profit incentives for scammers.
Mavenir’s SpamShield operates as a powerful SMS firewall – incorporating advanced monitoring, adaptive analytics, and real-time machine learning (ML) capabilities – that empowers Communication Service Providers (CSPs) to automatically block millions of fraudulent messages before they ever reach subscribers. SpamShield’s AI/ML detection algorithms adapt to current network conditions and subscriber behavior to continually detect spammer and fraudster attempts – enabling CSPs to quickly identify and act on potential threats and harmful events. This unique and innovative solution delivers an improved experience and greater security for customers, while protecting CSPs’ revenues from the negative costs of malicious activity.
Commenting on its successful spam reduction initiative, Anton Bonifacio, Chief Information Security Officer for Globe said: “Mavenir’s SpamShield technology has proven its ability to offer timely, precise, and effective threat detection and response, playing a central role in this dramatic reduction of spam and scam SMS traffic across our network to the immense benefit of all our customers. We now consider SpamShield an essential component of Globe’s anti-spam strategy moving forward, as we increase our innovation investment and strengthen our defenses against the tide of increasingly sophisticated fraudulent activity.”
Ilia Abramov, VP & GM of the Security Business Unit at Mavenir added: “Globe’s implementation of our SpamShield technology underlines its stringent and highly proactive approach to safeguarding customers, protecting users through the most robust and intelligent anti-spam messaging solution available today. The massive drop in blocked messages evidenced by these remarkable numbers shows how SpamShield achieves its transformative results in operation – making fraudulent activity prohibitively difficult and unprofitable for scammers, who then move on to easier and less protected targets including other operators and OTT channels such as WhatsApp. Globe is at the forefront of industry efforts to protect subscribers from this growing and ever-evolving array of threats, and we will continue to vigorously support its efforts to optimize communication safety and messaging authenticity in the Philippines.”
Notes to editors:
- Combating Messaging Scam and Fraud: A Telecom TV panel session with Globe recorded at MWC24: https://www.mavenir.com/resources/combating-messaging-scam-and-fraud/
About Globe:
Globe Telecom, Inc. is a leading full-service telecommunications company in the Philippines and publicly listed in the PSE with the stock symbol GLO. The company serves the telecommunications and technology needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connectivity, internet and managed services. It offers innovative digital solutions in the areas of fintech, healthtech, adtech, climatetech, shared services and venture capital. In 2019, Globe became a signatory to the United Nations Global Compact, committing to implement universal sustainability principles. Its principals are Ayala Corporation and Singtel, acknowledged industry leaders in the country and in the region.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529690737/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
